Vicor Technologies, Inc. (OTCBB: VCRT) is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i^® nonlinear algorithm.  Physician use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i^® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

Diagnostics that enable inexpensive, accurate, and early identification of disease states in at-risk populations prior to costly treatments for advanced disease or resulting from inaccurate identification are garnering increased attention in the current health care reform environment.

These populations are significant:

• 23.6 million diabetics
• 15 million at-risk cardiac patients
• 38 million trauma incidents

Vicor’s diagnostics are being developed to address those needs easily, accurately, and inexpensively. Vicor’s PD2i Analyzer™ has FDA 510(k) marketing clearance to both measure heart rate variability (HRV) for physician-determined use and be used specifically in cardiovascular disease testing. Physicians who have purchased the PD2i Analyzer™ are largely using it to test their diabetic patients for autonomic nervous system (ANS) dysfunction, also known as diabetic autonomic neuropathy or DAN. Cardiologists are using it to test their cardiovascular disease patients to risk stratify them for cardiac death resulting from arrhythmia or congestive heart failure. Current procedural terminology (CPT) codes enable physicians using the PD2i Analyzer™ to measure HRV to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.

Recent News

July 27 -Vicor Technologies Announces Agreement with ZOLL Medical Corporation

June 28 – Cardiology Researcher Dr. Wojciech Zareba Addresses Need to Improve Risk Stratification of Heart Failure Patients Eligible for ICD or CRT-D

June 16 – Study of Vicor Technologies’ PD2i^® Nonlinear Algorithm as Measure of Diabetic Autonomic Neuropathy Published in Clinical Neurophysiology

May 4 – Independent Research Demonstrates Ability of Vicor Technologies’ PD2i^® Nonlinear Algorithm to Identify a Wide Array of Medical Conditions and Disorders

April 26 – Vicor Technologies Reports First Quarter Revenues of $168,000; First Quarter Revenues Up 142% over Fourth Quarter and 88% of Full Year 2010

April 21 – Vicor Technologies’ PD2i^® Garners Interest from Researchers, Physicians at American Academy of Cardiology 60th Annual Scientific Session

April 19 – Vicor Technologies Receives FDA Clearance of 510(k) for its PD2i^® Nonlinear Algorithm and Software to be Used in Cardiovascular Disease Testing

Read More Vicor News…